The products analyze various datasets including a patient's genetic and metabolic profiles, clinical history, and demographics to inform prescribing decisions.
The Australian molecular diagnostics firm had stockholders' equity in excess of $2.5 million as of Aug. 28, in compliance with the Nasdaq listing rule.
The Australian molecular diagnostics firm said it has signed agreements sell 1,025,000 of its American Depository Shares to several institutional investors.
The company plans to use the proceeds for general product R&D, for reimbursement studies in the US, and for preparation for potential COVID-19 testing.
The funds will be used to launch new products in the US, as well as for R&D activities including the development of polygenic risk tests with partner TGen.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.